Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac


Sudha T., Bharali D. J. , Yalcin M., Darwish N. H. E. , Coskun M. D. , Keating K. A. , ...More

NANOMEDICINE, vol.12, no.3, pp.195-205, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.2217/nnm-2016-0315
  • Journal Name: NANOMEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.195-205
  • Keywords: cisplatin, integrin, nanotetrac, NDAT, tetraiodothyroacetic acid, urinary bladder carcinoma, ACTIVATED PROTEIN-KINASE, TETRAIODOTHYROACETIC ACID, THYROID-HORMONE, CANCER-CELLS, PLATINUM, INTEGRIN, RECEPTOR, GROWTH, DRUGS
  • Bursa Uludag University Affiliated: Yes

Abstract

Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin alpha v beta 3; alpha v beta 3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.